Spread through air spaces in non-small cell lung cancer: Experience of a tertiary hospital.

person Virginia Calvo Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain info_outline Virginia Calvo, Yago Garitaonaindia, Marta Martinez Cutillas, CRISTINA TRASEIRA, Isabel Redondo, Ramon Aguado, Ana Collazo Lorduy, Jose Luis Campo Cañaveral, Javier Martin Lopez, Aylen Vanessa Ospina Serrano, Mariola Blanco, Silvana Crowley, Alejandra Romero Roman, Mariana Gil Barturen, Consuelo Parejo, Mariano Provencio-Pulla

Authors person Virginia Calvo Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain info_outline Virginia Calvo, Yago Garitaonaindia, Marta Martinez Cutillas, CRISTINA TRASEIRA, Isabel Redondo, Ramon Aguado, Ana Collazo Lorduy, Jose Luis Campo Cañaveral, Javier Martin Lopez, Aylen Vanessa Ospina Serrano, Mariola Blanco, Silvana Crowley, Alejandra Romero Roman, Mariana Gil Barturen, Consuelo Parejo, Mariano Provencio-Pulla Organizations Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain, Hospital Puerta de Hierro Majadahonda, Majadahonda, Spain, Puerta de Hierro Majadahonda University Hospital, Majadahonda, Spain, H Puerta De Hierro (Spain), Madrid, Spain, Hospital Universitario Puerta de Hierro, Majadahonda, Spain, Hospital Universitario Puerta Hierro - Majadahonda (Spain), Majadahonda, Spain, Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, NY, Spain, Instituto de Investigacion Sanitaria Puerta de Hierro - Segovia de Arana. Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain, Hospital Universitario Puerta de Hierro, Madrid, Majadahonda, Spain, Hospital Universitario Puerta de Hierro, Madrid, Spain Abstract Disclosures Research Funding No funding received None. Background: Tumor spread through air space (STAS) is a novel pattern of invasion related to poor prognosis in non-small cell cancer (NSCLC). In 2015, Kyuichi Kadota first described spread through air spaces (STAS) as a novel histologic pattern of invasion related to poor prognosis NSCLC. The objective of this study is to describe the incidence of STAS in a surgical series of NSCLC patients resected in Hospital Universitario Puerta de Hierro-Majadahonda and identify the association of STAS with clinicopathological characteristics. Methods: Observational retrospective cohort study was performed from 2015 to 2021. Inclusion criteria were: age more than 18 years, histologically confirmed diagnosis of NSCLC, clinical stage I-IV and radical treatment with surgery. Descriptive analysis was performed. Results: 178 patients were included. 69.1% (123) were male, median age was 68.0 years. In relation to histological subtypes: 65.2% were adenocarcinoma, 22.5% squamous-cell carcinoma and 12.3% other histologies. Patients were classified by pathological stage: 71.9% were in stage I, 11.4% in stage II, 15.6% in stage III and 1.1% in stage IV. STAS was observed in the surgical specimen in 62 cases (34.8%). In Table-1 the association of STAS with clinicopathological characteristics is shown. Conclusions: In our study, we found statistically significant association between STAS and histological subtype and presence of lympho-vascular invasion. STAS were present more frequently in adenocarcinoma and were associated with more incidence of lympho-vascular invasion, as reported in other studies. More analysis are required for further description of this dissemination pattern and its implication in the prognosis of the patients. Association of STAS with clinicopathological characteristics. Non-STAS (n = 116) STAS (n = 62) p value Age (median, IQ 95%) 68.0 (67.0-70.0) 68.0 (66.0-71.0) 0.833 Sex Male: 81 (69.8%) Female: 35 (30.2%) Male: 42 (67.7%) Female: 20 (32.3%) 0.774 Smoking status* Current or former smoker: 94 (86.2%) Never smoker: 15 (13.8%) Non reported: 7 Current or former smoker: 53 (91.4%) Never smoker: 5 (8.6%) Non reported: 4 0.330 Histology Adenocarcinoma: 79 (68.1%) Squamous cell: 28 (24.1%) Other histologies: 9 (7.8%) Adenocarcinoma: 37 (59.7%) Squamous cell: 12 (19.3%) Other histologies: 13 (21.0%) 0.038* Stage I: 76 (71.0%) II: 14 (13.1%) III: 15 (14.0%) IV: 2 (1.9%) No reported: 9 I: 44 (73.3%) II: 5 (8.3%) III: 11 (18.4%) IV: 0 (0%) No reported: 2 0.499 SUVmax (median, IQ 95%) 5.9 (4.2-7.8) 6.0 (4.6-7.2) 0.584 Tumour diameter (median, IQ 95%) 2.2 (2.0-2.5) 2.5 (2.2-2.9) 0.339 Lymphatic invasion Present: 34 (29.6%) Absent: 82 (70.4%) Present: 34 (54.8%) Absent: 28 (45.2%) 0.004* Vascular invasion Yes: 35 (30.2%) No: 81 (69.8%) Yes: 33 (54.1%) No: 29 (45.9%) 0.004* pN N0: 98 (84.5%) N1: 8 (6.9%) N2: 9 (7.8%) No reported: 1 (0.8%) N0: 49 (79.0%) N1: 6 (9.7%) N2: 6 (9.7%) No reported: 1 (1.6%) 0.820